NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Cure Genetics

Cure Genetics

Private
SuzhouHealthcare & Life Scienceshttps://curegenetics.com/

Last Round

Series B

Jan 5, 2022

Total Funding Raised

$79.2M

Company Overview

Cure Genetics is a biotechnology company that develops cell and gene therapies for solid tumors and genetic diseases using its proprietary AIMS CAR-NKT and VELP AAV platforms.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

gene therapycell therapyCRISPRgene editingbiotech platformAAV vectorCAR-NKTsolid tumor therapygenetic disease treatmentdrug discoveryprecision medicinebiotech licensingnext-gen therapeuticsviral vector engineeringadvanced therapies

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cure Genetics Comps

Public and private peers based on sector, stage, and business model.

Cure Genetics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Cure Genetics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJan 5, 2022
Series AAug 6, 2018
AngelJan 1, 2017

Key People

Founding team and executive leadership

徐元元

创始人&CEO

Executive Team

Li Ren

Chief Technology Officer

Executive Team

Cure Genetics Investors

Notable investors and investment history

Cure Genetics investors
InvestorRounds
Oriza HoldingsSeries B
Blue Ocean Capital GroupSeries B
Advantech CapitalSeries B
Qiming Venture PartnersSeries B, Series A

Cure Genetics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Cure Genetics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Cure Genetics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSuzhou
Employee Range13
Year Founded2016
Last FundingJan 5, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.